Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteoporosis
Recent studies add new data to osteoporosis research
June 16th, 2005
Investigators in the United States and Japan have published new osteoporosis data. Study 1: An alpha(V)beta(3) integrin antagonist, L-000845704, has an antiresorptive effect on bone, the results of which are seen in increased lumbar bone mineral density, a Merck Research Laboratories study shows. The researchers suggest L-000845704 has potential as an antiosteoporosis drug. According to M.G. Murphy and colleagues, "The alpha(V)beta(3) integrin (vitronectin receptor) plays a pivotal role in bone resorption. We hypothesized that L-000845704, an alpha(V)beta(3) integrin antagonist, would potently inhibit bone resorption, thereby...
Source: Women's Health Weekly (2005-06-16)
|
